Amgen Inc at RBC Capital Markets Healthcare Conference Transcript
My name is Kennen MacKay. I'm a biotechnology analyst here at RBC, and it's my great pleasure to be joined next with Amgen. We have Arvind Sood, Global Head of Investor Relations at Amgen; as well as Dr. Levy, global Head of Clinical Development at Amgen. So before we jump into our sort of Q&A and fireside chat, I think the team are going to give some prepared remarks and some introductory statements, and then we'll have much more of a conversation here.
Great, Kennen. Good morning, everybody. So first of all, Kennen, thanks for inviting us to your conference. I'll just make some very brief comments, and then I'll turn it over to Elliott. So first of all, if you think of the last 5 years, we have established a pretty good track record of delivering against our objectives. And I think the Q1 in particular exemplifies that. In that, as we get into a more difficult environment from a pricing standpoint, we have been very focused
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
